Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
2041-2060 of 2,120 trials

Rheumatoid Arthritis: Lower Dose of Rituximab Study

We are evaluating whether a 200 mg dose of Rituximab every six months is as effective as the standard 1 g dose for managing rheumatoid arthritis. This study will help us understand its impact on disease activity and overall patient well-being.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementRheumatology

Small-Cell Lung Cancer: Tarlatamab Combination Study

We are testing a new treatment combining tarlatamab with durvalumab, carboplatin, and etoposide for patients with untreated extensive stage small-cell lung cancer. The goal is to see if this combination helps improve survival compared to standard treatment.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Breast Cancer Treatment: Elacestrant Study

We are studying whether Elacestrant alone is as effective as Elacestrant with ovarian function suppression in premenopausal women with early-stage ER+/HER2- breast cancer. The trial also looks at the safety of these treatment options.

Breast Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Exenatide for Early Parkinson’s Disease Progression

We are studying whether Exenatide can slow down the progression of symptoms in people with early Parkinson’s disease. The trial will also assess the safety of this treatment over time.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyNeurology

Bisphosphonate Treatment for Primary Hyperparathyroidism

We are studying whether bisphosphonate treatment before parathyroid surgery can improve bone, kidney, and heart health one year after the procedure. This trial compares the treatment to a placebo to see if there are any benefits.

Primary Hyperparathyroidism1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Clonidine for Preventing Agitation in Young Children After Anesthesia

We are studying whether clonidine can help reduce agitation and pain in children under one year after surgery. The trial also examines its safety and effects on nausea and opioid use.

Postoperative Agitation≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyPediatrics

Stem Cell Transplant: New T Cell Therapy

We are studying a new treatment using special T cells to help prevent complications in patients receiving stem cell transplants from siblings. The goal is to see if this approach can safely reduce the need for other medications.

Healthy Participants6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyInfectious DiseasesInternal Medicine

Daratumumab for Myalgic Encephalomyelitis (ME/CFS)

We are studying whether the drug daratumumab can help reduce symptoms in people with moderate to severe ME/CFS. The trial will also assess its safety compared to a placebo.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteInfectious DiseasesNeurology

Lung Cancer: Nivolumab with Ipilimumab and Chemotherapy

We are studying a new way to administer nivolumab alongside ipilimumab and chemotherapy for patients with untreated metastatic or recurrent lung cancer. The trial aims to understand how the body reacts to this combination and its safety.

Non-small cell lung cancer6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

PMM2-CDG: GLM101 Treatment Study

We are investigating whether weekly doses of GLM101 can improve movement and coordination in people with PMM2-CDG. The study will also evaluate the safety of this new treatment compared to a placebo.

Congenital Disorder of Glycosylation (CDG)6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHepatologyNeurology

Hairy Cell Leukemia: Vemurafenib and Rituximab Study

We are exploring a new treatment combination for hairy cell leukemia that may be less toxic than standard chemotherapy. This study aims to see if it is just as effective while monitoring patient safety and quality of life.

Hairy Cell Leukaemia>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Hodgkin Lymphoma: Ruxolitinib with Brentuximab or Pembrolizumab

We are studying the combination of ruxolitinib with either brentuximab or pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma. The goal is to see if this combination improves treatment response and safety.

Recurrent or Refractory Classical Hodgkin Lymphoma3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: Bleximenib, Venetoclax, and Azacitidine Study

We are studying a combination of three medications for people with newly diagnosed acute myeloid leukemia who cannot receive intensive chemotherapy. The aim is to see if this combination works better than the standard treatment alone.

Acute Myeloid LeukemiaConfirmation phase (III)Investigational MedicinesPartially RemoteHematologyOncology

Prostate Cancer: JSB462 and Lutetium Combination Study

We are studying a new treatment combining JSB462 with lutetium for adult men with advanced prostate cancer. The goal is to see how well this combination works and its safety compared to standard treatment.

Metastatic Castration-Resistant Prostate Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Ravulizumab for Pediatric IgA Nephropathy

We are studying how Ravulizumab works in children with Primary Immunoglobulin A Nephropathy. This research may help us understand its effects and safety in younger patients.

Immunoglobulin A Nephropathy6-12 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNephrologyPediatrics

Breast Cancer Treatment: Sac-TMT vs. Standard Chemotherapy

We are studying a new treatment for high-risk early-stage breast cancer to see if it works better than standard chemotherapy combined with pembrolizumab. This trial is for individuals with triple-negative or hormone receptor-low positive breast cancer.

Triple Negative Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Ulcerative Colitis: Testing OD-07656

We are studying a new treatment called OD-07656 for people with moderately to severely active ulcerative colitis. The trial aims to evaluate its safety and effectiveness compared to another therapy.

Ulcerative ColitisEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyInternal Medicine

Ulcerative Colitis: Mirikizumab with Tirzepatide

We are studying whether combining mirikizumab with tirzepatide helps adults with moderately to severely active ulcerative colitis and obesity achieve better remission and weight loss than mirikizumab alone.

Obesity or OverweightUlcerative Colitis1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesPartially RemoteEndocrinologyGastroenterology

Crohn’s Disease: Mirikizumab with Tirzepatide

We are studying whether a combination of mirikizumab and tirzepatide helps adults with moderately to severely active Crohn’s disease achieve better remission and weight loss than mirikizumab alone.

Crohn’s DiseaseObesity or Overweight1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterology

TAILORED-PROM: Personalized Treatment for Preterm Premature Rupture of Membranes

We are studying if a customized antibiotic and steroid therapy can help prolong pregnancy and improve outcomes for mothers and newborns. This approach may reduce unnecessary antibiotic use compared to standard treatments.

Preterm Premature Rupture of Membranes>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsInfectious Diseases